title: GFR decline as an alternative end point in clinical trials to prevent ESRD: are we increasing treatment uncertainty for the sake of feasibility?
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Sontrop
authors.forename: Ahmed A
authors.initials: AA
authors.lastname: Al-Jaishi
authors.forename: Amit X
authors.initials: AX
authors.lastname: Garg
mesh_terms: D023381:Endpoint Determination / Q000379:methods*; D005919:Glomerular Filtration Rate / Q000502:physiology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis* / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods*